IP Library Granted Patent US 10,617,505
Granted Patent B2
US 10,617,505 · App. 14/432,390 · Granted Apr 14, 2020

Conductive and degradable implant for pelvic tissue treatment

Inventor: Guangjian Wang (Falcon Heights, MN)
Assignee: Boston Scientific Scimed, Inc.
A61F2/0063A61F2/0045A61L31/06A61L31/10A61L31/14A61L31/148A61N1/0514A61F2210/0004A61F2250/0001A61N1/36007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,617,505
App. No.
14/432,390
Granted
Apr 14, 2020
Kind
B2
Abstract

Described is a pelvic implant comprising a biodegradable conductive mesh. The mesh can include biodegradable and electrically conductive polymer, and can be stimulated with a current to generate an electric field to promote an improved tissue response following placement of the implant. The invention also describes methods and systems including the pelvic implant comprising a biodegradable conductive mesh for the treatment of pelvic floor conditions. Implants of the invention provide benefits relating to improved tissue integration into the mesh, resulting in pelvic tissue reconstruction. Tissue reconstruction and elimination of the mesh materials can lead to a better clinical outcome for the patient.

Claims (30)

1. A medical device:

a mesh implant having a plurality of biodegradable conductive fibers, the plurality of biodegradable conductive fibers including a first type filament and a second type filament, the first type filament being a conductive polymer and the second type filament being a mixture of a coated biodegradable conductive fiber including a core constructed from a biodegradable polymer and a conductive coating constructed from an electrically conductive polymer, the conductive coating covering less than 50% of an outer surface of the core,

the mesh implant having a first end portion including a first end and a second end portion including a second end, the mesh implant including a first portion, a second portion, and a third portion, the first portion being disposed on the first end portion and defining a first electrode segment having first coated biodegradable conductive fiber portions, the second portion being disposed on the second end portion and defining a second electrode segment having second coated biodegradable conductive fiber portions, the third portion being disposed between the first end portion and the second end portion and having third coated biodegradable conductive fiber portions, the first electrode segment and the second electrode segment having greater concentrations of the conductive polymer than the third portion of the mesh implant;

a first lead configured to be coupled to the first electrode segment; and

a second lead configured to be coupled to the second electrode segment.

2. The medical device of claim 1 , wherein the biodegradable polymer is selected from the group consisting of polyesters, polyhydroxyalkanoates, polyorthoesters, polyalkeneanhydrides, and polyanhydrides.

3. The medical device of claim 1 , wherein the coated biodegradable conductive fiber is in the form of a monofilament.

4. The medical device of claim 1 , wherein the conductive coating has a thickness in a range of about 0.5 μm to about 25 μm.

5. The medical device of claim 1 , wherein the mesh implant includes a woven structure.

6. The medical device of claim 1 , wherein the conductive coating has a thickness in a range of about 1 μm to about 10 μm.

7. The medical device of claim 1 , wherein the conductive coating includes a concentration of polyaniline in a range of 0.5 to about 10%.

8. The medical device of claim 1 , wherein the electrically conductive polymer is selected from the group consisting of polyaniline, polypyrrole and polythiophene.

9. The medical device of claim 1 , wherein the electrically conductive polymer comprises polypyrrole.

10. The medical device of claim 1 , wherein the electrically conductive polymer comprises polyaniline.

11. The medical device of claim 1 , wherein the electrically conductive polymer covers less than 10% of the outer surface of the core.

12. The medical device of claim 1 , wherein the electrically conductive polymer covers less than 5% of the outer surface of the core.

13. The medical device of claim 1 , wherein the electrically conductive polymer covers only one side of the outer surface of the core.

14. The medical device of claim 13 , wherein the covered electrically conductive polymer is continuous from one electrode attachment to another electrode attachment point.

15. A system comprising:

a mesh implant configured for placement at a pelvic floor tissue, the mesh implant including a plurality of biodegradable conductive fibers, the plurality of biodegradable conductive fibers including a first type filament and a second type filament, the first type filament being a conductive polymer and the second type filament being a mixture of a coated biodegradable conductive fiber including a core constructed from a biodegradable polymer and a conductive coating constructed from an electrically conductive polymer, the electrically conductive polymer being disposed around an outer surface of the core,

the mesh implant having a first end portion including a first end and a second end portion including a second end, the mesh implant including a first portion, a second portion, and a third portion, the first portion being disposed on the first end portion and defining a first electrode segment having first coated biodegradable conductive fiber portions, the second portion being disposed on the second end portion and defining a second electrode segment having second coated biodegradable conductive fiber portions, the third portion being disposed between the first end portion and the second end portion and having third coated biodegradable conductive fiber portions, the first electrode segment and the second electrode segment having greater concentrations of the conductive polymer than the third portion of the mesh implant;

a first lead configured to be coupled to the first electrode segment;

a second lead configured to be coupled to the second electrode segment; and

an electrical stimulator unit coupled to the first lead and the second lead, the electrical stimulator unit configured to generate a current through the mesh implant.

16. The system of claim 15 , wherein the monofilament includes at least one groove along a length of the monofilament.

17. A method for treating pelvic floor tissues, the method comprising:

(a) placing a mesh implant at a pelvic floor tissue, the mesh implant including a plurality of biodegradable conductive fibers, the plurality of biodegradable conductive fibers including a first type filament and a second type filament, the first type filament being a conductive polymer and the second type filament being a mixture of a coated biodegradable conductive fiber including a core constructed from a biodegradable polymer and a conductive coating constructed from an electrically conductive polymer, the conductive coating covering less than 50% of an outer surface of the core,

the mesh implant having a first end portion and a second end portion, the mesh implant consisting of a first portion, a second portion, and a third portion, the first portion being disposed on the first end portion and defining a first electrode segment having first coated biodegradable conductive fiber portions, the second portion being disposed on the second end portion and defining a second electrode segment having second coated biodegradable conductive fiber portions, the third portion being disposed between the first end portion and the second end portion and having third coated biodegradable conductive fiber portions, the first electrode segment and the second electrode segment having greater concentrations of the conductive polymer than the third portion of the mesh implant, wherein a first lead is coupled to the first electrode segment, and a second lead is coupled to the second electrode segment;

(b) generating a current through the mesh implant to promote a tissue healing response; and

(c) allowing the mesh implant to degrade at the site of placement.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.); ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067240/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2017
From: ASTORA WOMEN'S HEALTH, LLC; ENDO HEALTH SOLUTIONS INC.; ASTORA WOMEN'S HEALTH HOLDINGS, LLC
To: BOSTON SCIENTIFIC CORPORATION
Reel/Frame 043777/0895 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2017
From: BOSTON SCIENTIFIC CORPORATION
To: BOSTON SCIENTIFIC SCIMED, INC.
Reel/Frame 043778/0167 →
SECURITY INTEREST Recorded Jun 8, 2017
From: ASTORA WOMEN'S HEALTH, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 042743/0278 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA NAME PREVIOUSLY RECORDED AT REEL: 037300 FRAME: 0728. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Apr 21, 2017
From: AMS RESEARCH CORPORATION
To: AMS RESEARCH, LLC
Reel/Frame 042308/0630 →
CHANGE OF NAME Recorded Jan 18, 2016
From: APHRODITE WOMEN'S HEALTH, LLC
To: ASTORA WOMEN'S HEALTH, LLC
Reel/Frame 037551/0749 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2016
From: AMS RESEARCH, LLC
To: APHRODITE WOMEN'S HEALTH, LLC
Reel/Frame 037551/0626 →
CHANGE OF NAME Recorded Dec 15, 2015
From: AMS RESEARCH CORPATION
To: AMS RESEARCH, LLC
Reel/Frame 037300/0728 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2015
From: WANG, GUANGJIAN
To: AMS RESEARCH CORPORATION
Reel/Frame 035882/0161 →
Continuity (2)
Provisional Application 61708434 · Oct 1, 2012
Related Publication 20150238300A1 · Aug 27, 2015